Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy

J. S. Little, R. S. Foster, T. M. Ulbright, J. P. Donohue, F. K. Mostofi, R. R. Bahnson, J. P. Richie

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Approximately 30% of patients with disseminated testis cancer who receive platinum-based chemotherapy will experience normalization of tumor markers but have persistent, radiographically evident disease in the retroperitoneum. These patients usually undergo retroperitoneal lymph node dissection. Of 557 patients undergoing post-chemotherapy retroperitoneal lymph node dissection at our university medical center 45 (8.1%) had neoplastic elements distinct from the classical germ cell tumor types within the resected specimens. Examples include various sarcomas in 19 patients (3.7%), other nonsarcomatous nongerm cell cancers in 18 (3.2%) and cystic atypical choriocarcinoma in 8 (1.4%). No distinct patient characteristics or histological patterns in the primary tumor are predictive of these unusual findings in the retroperitoneal lymph node dissection specimen, although sampling error in the orchiectomy specimen could be the reason for this lack of correlation. Surgical resection of these chemoresistant tumors is potentially curative, with disease-free survival in 13 of 19 patients (68.4%) with sarcoma, 10 of 18 (55.6%) with nonsarcomatous cancer and 7 of 8 (87.5%) with cystic atypical choriocarcinoma at a mean followup of 30.6, 42.5 and 24.7 months, respectively.

Original languageEnglish (US)
Pages (from-to)1144-1151
Number of pages8
JournalJournal of Urology
Volume152
Issue number4
StatePublished - Jan 1 1994

Fingerprint

Testicular Neoplasms
Lymph Node Excision
Drug Therapy
Neoplasms
Choriocarcinoma
Sarcoma
Orchiectomy
Selection Bias
Germ Cell and Embryonal Neoplasms
Tumor Biomarkers
Platinum
Disease-Free Survival

Keywords

  • chemotherapy
  • sarcoma
  • teratoma
  • testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Little, J. S., Foster, R. S., Ulbright, T. M., Donohue, J. P., Mostofi, F. K., Bahnson, R. R., & Richie, J. P. (1994). Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy. Journal of Urology, 152(4), 1144-1151.

Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy. / Little, J. S.; Foster, R. S.; Ulbright, T. M.; Donohue, J. P.; Mostofi, F. K.; Bahnson, R. R.; Richie, J. P.

In: Journal of Urology, Vol. 152, No. 4, 01.01.1994, p. 1144-1151.

Research output: Contribution to journalArticle

Little, JS, Foster, RS, Ulbright, TM, Donohue, JP, Mostofi, FK, Bahnson, RR & Richie, JP 1994, 'Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy', Journal of Urology, vol. 152, no. 4, pp. 1144-1151.
Little, J. S. ; Foster, R. S. ; Ulbright, T. M. ; Donohue, J. P. ; Mostofi, F. K. ; Bahnson, R. R. ; Richie, J. P. / Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy. In: Journal of Urology. 1994 ; Vol. 152, No. 4. pp. 1144-1151.
@article{1a50d31f939a43c1b513c34409451b2e,
title = "Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy",
abstract = "Approximately 30{\%} of patients with disseminated testis cancer who receive platinum-based chemotherapy will experience normalization of tumor markers but have persistent, radiographically evident disease in the retroperitoneum. These patients usually undergo retroperitoneal lymph node dissection. Of 557 patients undergoing post-chemotherapy retroperitoneal lymph node dissection at our university medical center 45 (8.1{\%}) had neoplastic elements distinct from the classical germ cell tumor types within the resected specimens. Examples include various sarcomas in 19 patients (3.7{\%}), other nonsarcomatous nongerm cell cancers in 18 (3.2{\%}) and cystic atypical choriocarcinoma in 8 (1.4{\%}). No distinct patient characteristics or histological patterns in the primary tumor are predictive of these unusual findings in the retroperitoneal lymph node dissection specimen, although sampling error in the orchiectomy specimen could be the reason for this lack of correlation. Surgical resection of these chemoresistant tumors is potentially curative, with disease-free survival in 13 of 19 patients (68.4{\%}) with sarcoma, 10 of 18 (55.6{\%}) with nonsarcomatous cancer and 7 of 8 (87.5{\%}) with cystic atypical choriocarcinoma at a mean followup of 30.6, 42.5 and 24.7 months, respectively.",
keywords = "chemotherapy, sarcoma, teratoma, testicular neoplasms",
author = "Little, {J. S.} and Foster, {R. S.} and Ulbright, {T. M.} and Donohue, {J. P.} and Mostofi, {F. K.} and Bahnson, {R. R.} and Richie, {J. P.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "152",
pages = "1144--1151",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Unusual neoplasms detected in testis cancer patients undergoing post- chemotherapy retroperitoneal lymphadenectomy

AU - Little, J. S.

AU - Foster, R. S.

AU - Ulbright, T. M.

AU - Donohue, J. P.

AU - Mostofi, F. K.

AU - Bahnson, R. R.

AU - Richie, J. P.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Approximately 30% of patients with disseminated testis cancer who receive platinum-based chemotherapy will experience normalization of tumor markers but have persistent, radiographically evident disease in the retroperitoneum. These patients usually undergo retroperitoneal lymph node dissection. Of 557 patients undergoing post-chemotherapy retroperitoneal lymph node dissection at our university medical center 45 (8.1%) had neoplastic elements distinct from the classical germ cell tumor types within the resected specimens. Examples include various sarcomas in 19 patients (3.7%), other nonsarcomatous nongerm cell cancers in 18 (3.2%) and cystic atypical choriocarcinoma in 8 (1.4%). No distinct patient characteristics or histological patterns in the primary tumor are predictive of these unusual findings in the retroperitoneal lymph node dissection specimen, although sampling error in the orchiectomy specimen could be the reason for this lack of correlation. Surgical resection of these chemoresistant tumors is potentially curative, with disease-free survival in 13 of 19 patients (68.4%) with sarcoma, 10 of 18 (55.6%) with nonsarcomatous cancer and 7 of 8 (87.5%) with cystic atypical choriocarcinoma at a mean followup of 30.6, 42.5 and 24.7 months, respectively.

AB - Approximately 30% of patients with disseminated testis cancer who receive platinum-based chemotherapy will experience normalization of tumor markers but have persistent, radiographically evident disease in the retroperitoneum. These patients usually undergo retroperitoneal lymph node dissection. Of 557 patients undergoing post-chemotherapy retroperitoneal lymph node dissection at our university medical center 45 (8.1%) had neoplastic elements distinct from the classical germ cell tumor types within the resected specimens. Examples include various sarcomas in 19 patients (3.7%), other nonsarcomatous nongerm cell cancers in 18 (3.2%) and cystic atypical choriocarcinoma in 8 (1.4%). No distinct patient characteristics or histological patterns in the primary tumor are predictive of these unusual findings in the retroperitoneal lymph node dissection specimen, although sampling error in the orchiectomy specimen could be the reason for this lack of correlation. Surgical resection of these chemoresistant tumors is potentially curative, with disease-free survival in 13 of 19 patients (68.4%) with sarcoma, 10 of 18 (55.6%) with nonsarcomatous cancer and 7 of 8 (87.5%) with cystic atypical choriocarcinoma at a mean followup of 30.6, 42.5 and 24.7 months, respectively.

KW - chemotherapy

KW - sarcoma

KW - teratoma

KW - testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0028048521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028048521&partnerID=8YFLogxK

M3 - Article

C2 - 8072083

AN - SCOPUS:0028048521

VL - 152

SP - 1144

EP - 1151

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -